Figure 5.

Effect of Cabozantinib on DCs. (A) Modulation of β-catenin in DCs upon Cabozantinib treatment. Western blot analysis in iDCs and mDCs, untreated (NT) or treated with 2.5 μg/ml of Cabozantinib (2.5 CB) to detect β-catenin protein (92 kDa). β-Actin (43kDa) was employed as internal reference standard. Band intensity was measured by ImageJ software. Histograms represent normalization of the intensity values obtained as ratio between the sample value and the control. (B) The histograms represent the average of MFI values of DC phenotypic markers from healthy donor. The monocytes after 4 days of differentiation were treated with Cabozantinib (2.5 μg/ml), and at day 5, iDCs were collected and matured with cytokine cocktail (rhIL1β, IL6, TNFα, and PGE₂). The concentration of Cabozantinib used for the culture corresponds to serum levels achieved in TKI-treated patients. The histograms correspond to the average of MFI values among six healthy donors ± SEM. (C) Uptake of the fluorescein isothiocyanate (FITC)-dextran by iDCs cultured in presence or absence of Cabozantinib. Results are reported as ratio between the mean fluorescence intensity (MFI) obtained incubating the cells with FITC-dextran for 1 h at 37°C and 4°C. *p < 0.05; **p < 0.01, Student’s t-test.